A RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY COMPARING THE EFFECT OF ONCE-WEEKLY DULAGLUTIDE WITH ONCE-DAILY LIRAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES (AWARD-6: ASSESSMENT OF WEEKLY ADMINISTRATION OF LY2189265 IN DIABETES-6)

A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes (AWARD-6)

Approval Date: 8/23/2012

Principal Investigator: Wendy Miller, MD

The purpose of the study is to assess the benefits and risks of once-weekly dulaglutide compared to once-daily liraglutide in participants with type 2 diabetes who have inadequate glycemic control on metformin.

Eligibility:

Each study has criteria to determine whether someone is eligible to participate in a clinical trial.  The study physician can best assess if you meet the eligibility criteria of this clinical study.  More information can also be found on clinicaltrials.gov at http://clinicaltrials.gov/show/NCT01624259.

Contact Person:
Catherine Coleman, RN, Res Coordinator
248-655-5865

Status of Clinical Trial:
open and enrolling